Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):563-4. doi: 10.1097/QAI.0b013e318183ac9c.
No abstract available

Publication types

  • Comment
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / pharmacology
  • Anti-HIV Agents / therapeutic use
  • Darunavir
  • Drug Resistance, Multiple, Viral
  • HIV Infections / drug therapy*
  • HIV-1 / drug effects
  • HIV-1 / genetics
  • Humans
  • Lopinavir
  • Mutation
  • Protease Inhibitors / administration & dosage
  • Protease Inhibitors / pharmacology*
  • Protease Inhibitors / therapeutic use
  • Pyrimidinones / administration & dosage*
  • Pyrimidinones / pharmacology
  • Pyrimidinones / therapeutic use
  • Ritonavir / administration & dosage*
  • Ritonavir / pharmacology
  • Ritonavir / therapeutic use
  • Sulfonamides / administration & dosage*
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use

Substances

  • Anti-HIV Agents
  • Protease Inhibitors
  • Pyrimidinones
  • Sulfonamides
  • Lopinavir
  • Ritonavir
  • Darunavir